We also found that PIKfyve inhibition improved anti-PD-1 efficacy against syngeneic pancreatic tumors established with orthotopic injection of KPC1361 cells (Fig. 4B), which translated into improved overall survival (SI Appendix, Fig. S5A). Here, PIKFYVE is linked to pancreatic neoplasm.